Washington University School of Medicine
Overdose is a national top-three leading cause of pregnancy-associated death, and maternal substance use disorder (SUD) accounts for an estimated $1.5 billion in healthcare spending each year. Treatment with medication and behavioral therapy lowers morbidity and overdose risk. However, studies have shown 55% to 80% of patients stop treatment within one year postpartum. Additionally, as a result of systemic inequities, historically marginalized patients are at greatest risk of overdose or death. We are conducting a study at WashU Medicine and University of Maryland, Baltimore clinics that offer prenatal care, addiction treatment, and extended postpartum support for patients facing the challenges of a SUD. Study participants will complete a structured screening and management of their social needs, and then will be randomly assigned to continue their usual care or to participate in a contingency management program, which provides incentives to continue treatment.
Inclusion Criteria: * Confirmed viable intrauterine pregnancy at any gestational age; OR postpartum with at least six months remaining until 365 days after deliver * Diagnosis of SUD as defined by DSM-5 and/or as documented in the clinical record * 18 years of age or older * Two or more positive domains in first screening for social drivers of health * Receiving ongoing care at participating study site Exclusion Criteria: * Declining follow-up care at participating study site * Participated in R61 pilot study for CM * Requiring immediate hospitalization for unstable medical or psychiatric c…
12 weekly sessions, 15-20 minutes each
Screening for social drivers of health, documentation of applicable z-codes in the medical record and social needs linkage
The payment is part of what this study tests.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.